Predict your next investment

Incubator/Accelerator
HEALTHCARE | Drug Development
nestlehealthscience.com

See what CB Insights has to offer

Investments

17

Portfolio Exits

4

Partners & Customers

10

About Nestle Health Science

Nestle Health Science, a wholly-owned subsidiary of Nestle, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. Its portfolio of nutrition solutions, diagnostics, devices and drugs, targets a number of health areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy ageing, and gastrointestinal and brain health. Nestle Health Science employs around 3,000 people worldwide and is headquartered in Vevey, Switzerland.

Nestle Health Science Headquarter Location

Avenue Nestlé 55

Vevey, 1800,

Switzerland

+41 21 924 1111

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nestle Health Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Nestle Health Science in 1 Expert Collection, including Sleep Health & Wellness.

S

Sleep Health & Wellness

798 items

These companies aim to assess or improve the quantity/quality of sleep, or use sleep data in the monitoring or diagnosis of other health conditions.

Nestle Health Science Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nestle Health Science Rank

Latest Nestle Health Science News

Trending topics: The top 10 trends in APAC’s health and nutrition industry in 2021

Dec 21, 2021

By Guan Yu Lim Here are our top 10 trends stories APAC’s health and nutrition industry this year, spanning the NMN craze, halal products, and e-commerce strategy. 1. ‘The longevity pill’: NMN craze in China drove sales spurt for US, Japanese, NZ brands​ China’s increasing interest ​ in nicotinamide mononucleotide (NMN), colloquially known as ‘the longevity pill’ in the country, have push sales to a new high for brands from the US brand Doctor’s Best, New Zealand’s EZZ, and Japan’s NADaltus. According to the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMPHIE),  the influx of NMN products from the US ​ had boosted the country’s overall exports of nutraceuticals into China in this year. The interest in NMN first started after China health foods firm Xiamen Kingdomway introduced its subsidiary firm – Doctor’s Best’s product during the mid-year, Charles Diao, regulatory manager at US-China Health Products Association, noted. Kingdomway said its plans for Doctor’s Best in China was to expand its NMN product line to satisfy needs of different people and sales channels. 6. NAD+ precursors: Hong Kong, ANZ and China help drive Chromadex results as firm fires warning over NMN explosion​ Nicotinamide riboside (NR) supplement specialist Chromadex’s had posted strong regional and global FY2020 financials, but the firm issued a warning ​ of ‘concerning behaviour’ from some nicotinamide mononucleotide (NMN) brands, especially in China. Chromadex’s FY2020 net sales hit US$59.3m, up 28 per cent yoy, with personal healthcare retail chain AS Watson’s activities in Hong Kong its biggest sales driver in APAC. The company also recorded a gross profit of US$35.2m last year, up from US$25.7m in 2019. The nicotinamide riboside (NR) firm sells its ingredient through the trademark Niagen, while its finished product is sold under the brand Tru Niagen. It first ventured into APAC, starting with Hong Kong four years ago. 7. Unilever’s exclusive insights: Four key trends driving APAC’s online supplements growth​ Unilever identified four emerging trends from online sales of health supplements ​ across Asia Pacific, including the younger generation viewing vitamins and supplements as lifestyle products, and how online shopping events such as Super Brand Days were effective in attracting new consumers, it said in an exclusive interview. The FMCG giant had been on an acquisition spree for health supplement brands in recent years, with  OLLY ​,  Onnit ​,  SmartyPants ​, and Liquid I.V as examples. Addressing a wide variety of health concerns, these brands consist of products for beauty, immunity, physical fitness, mental wellbeing, catered to consumers of different ages and even pets. 8. Daigou still slow: Infant nutrition brands drove sales at mother-and-baby stores, e-commerce in China​ Strengthening distribution in mother-and-baby stores, complemented by effective local e-commerce and cross-border e-commerce (CBEC) operations would be the way for overseas infant formula brands to thrive in China ​, with the daigou channel still seeing weak signs of recovery amid travel restrictions, an industry analyst said. Since the COVID-19 outbreak, there have been significant changes in the way consumers purchase infant formula products. Pre-COVID, e-commerce was the popular purchase channel of infant formulas in tier one and two cities, while mother-and-baby stores was the go-to in third and fourth tier cities, Michael Norris, research and strategy manager at Agency China told NutraIngredients-Asia.​ With the pandemic, the uptake of e-commerce have picked up in the lower tier cities as well. 9. WATCH: Nestle Health Science, Esperer Nutrition on NPD for glucose control nutrition via new formats and ingredients​ New product development for glucose control and diabetes prevention nutrition werecutting across new dosage formats ​, the use of plant-based ingredients, pre/probiotics, and even the inclusion of artificial intelligence (AI) to make health decisions, according to global nutrition giant Nestle Health Science and India start-up Esperer Nutrition. Characterised by a high fasting glucose level – above 7.0 mmol/L – diabetes is a common chronic disease seen in many parts of Asia partly due to a carbohydrate-loaded diet. It ranks high on the national health care agenda for some countries, such as Singapore. This was why Nestle Health Science has earmarked the South East Asia region as the launchpad for its new glucose control product. 10. Nutra trends 2021: GNC, Nestle, Kirin, GO Healthy weigh in on this year’s key developments​ Major nutra brands GNC, Nestle, GO Healthy, and Kirin have shared with us the key trends ​ they believe would propel the sector in 2021. Immune health was said to continue to see a stable and strong consumer demand, as consumers continue to prioritise immunity amid the pandemic. This was according to GO Healthy, which said it saw a significant lift in the sales of its immune products last year. Examples include its GO Vitamin C, GO Vitamin D3 and GO Zinc Complex products. “For 2021, we are looking to strengthen our positioning with the key immunity products, with a specific focus on the ingredients that’re popular during the pandemic, whilst maintaining our high strength, convenient 1-A-Day brand positioning,”​ Kevin Anstiss, marketing and innovation director said. Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Nestle Health Science Investments

17 Investments

Nestle Health Science has made 17 investments. Their latest investment was in ProciseDx as part of their Convertible Note on July 7, 2021.

CBI Logo

Nestle Health Science Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/13/2021

Convertible Note

ProciseDx

$13M

Yes

3

6/25/2020

Series E

Enterome

$52.6M

No

6

2/5/2020

PIPE - III

Aimmune Therapeutics

$200M

No

16

1/9/2020

Incubator/Accelerator

Subscribe to see more

Subscribe to see more

10

1/9/2020

Incubator/Accelerator

Subscribe to see more

Subscribe to see more

10

Date

7/13/2021

6/25/2020

2/5/2020

1/9/2020

1/9/2020

Round

Convertible Note

Series E

PIPE - III

Incubator/Accelerator

Incubator/Accelerator

Company

ProciseDx

Enterome

Aimmune Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$13M

$52.6M

$200M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

6

16

10

10

Nestle Health Science Portfolio Exits

4 Portfolio Exits

Nestle Health Science has 4 portfolio exits. Their latest portfolio exit was Aimmune Therapeutics on August 31, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/31/2020

Acq - P2P

$99M

18

7/10/2019

Acquired - II

Subscribe to see more

Subscribe to see more

10

5/9/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/26/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/31/2020

7/10/2019

5/9/2019

6/26/2015

Exit

Acq - P2P

Acquired - II

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

18

10

10

10

Nestle Health Science Acquisitions

9 Acquisitions

Nestle Health Science acquired 9 companies. Their latest acquisition was Dr. Schar - Mevalia Brand on July 09, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/9/2021

$99M

Acquired Unit

1

7/9/2021

Subscribe to see more

$99M

Subscribe to see more

10

5/10/2021

Private Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

10/17/2020

Subscribe to see more

$99M

Subscribe to see more

10

8/18/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/9/2021

7/9/2021

5/10/2021

10/17/2020

8/18/2020

Investment Stage

Private Equity

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired Unit

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Nestle Health Science Partners & Customers

10 Partners and customers

Nestle Health Science has 10 strategic partners and customers. Nestle Health Science recently partnered with Seres Therapeutics on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/1/2021

Licensor

Seres Therapeutics

United States

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

Nestlé Health Science already has commercial rights to Seres Therapeutics , Inc. ' investigational treatments for CDI and inflammatory bowel disease outside of the U.S. and Canada , and with this expansion , Nestlé Health Science becomes Seres Therapeutics , Inc. ' global collaborator in SER-109 .

2

1/26/2021

Licensor

Senda Biosciences

United States

1

8/14/2020

Partner

Epitomee Medical

Israel

Israeli Biomed Epitomee partners with Nestle to market globally coveted weight loss solution

Global leader in nutritional science Nestle Health Science announced that it has signed a strategic partnership with Israeli based Biomed company , Epitome Medical , which was founded in 2005 by Shimon Eckhouse , Ph.D. .

2

4/20/2020

Partner

The Hut Group

United Kingdom

Subscribe to see more

Subscribe to see more

10

2/5/2020

Licensor

Valbiotis

France

Subscribe to see more

Subscribe to see more

10

Date

7/1/2021

1/26/2021

8/14/2020

4/20/2020

2/5/2020

Type

Licensor

Licensor

Partner

Partner

Licensor

Business Partner

Seres Therapeutics

Senda Biosciences

Epitomee Medical

The Hut Group

Valbiotis

Country

United States

United States

Israel

United Kingdom

France

News Snippet

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

Nestlé Health Science already has commercial rights to Seres Therapeutics , Inc. ' investigational treatments for CDI and inflammatory bowel disease outside of the U.S. and Canada , and with this expansion , Nestlé Health Science becomes Seres Therapeutics , Inc. ' global collaborator in SER-109 .

Israeli Biomed Epitomee partners with Nestle to market globally coveted weight loss solution

Global leader in nutritional science Nestle Health Science announced that it has signed a strategic partnership with Israeli based Biomed company , Epitome Medical , which was founded in 2005 by Shimon Eckhouse , Ph.D. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

2

10

10

Nestle Health Science Team

6 Team Members

Nestle Health Science has 6 team members, including current Chief Executive Officer, President, Greg Behar.

Name

Work History

Title

Status

Greg Behar

Boehringer Ingelheim, Novartis, and Nestle

Chief Executive Officer, President

Current

Caroline Charlesworth

Chief Executive Officer

Current

Eric Bouchard

Chief Financial Officer

Current

Mary Christ MD MBA

Chief Financial Officer

Current

Dawn Setlock

Nestle, Boehringer Ingelheim, and AstraZeneca

Chief Marketing Officer

Current

Name

Greg Behar

Caroline Charlesworth

Eric Bouchard

Mary Christ MD MBA

Dawn Setlock

Work History

Boehringer Ingelheim, Novartis, and Nestle

Nestle, Boehringer Ingelheim, and AstraZeneca

Title

Chief Executive Officer, President

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer

Chief Marketing Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.